CAR-T Therapy: What’s in the CARds? – Module 1

CME: 1.0

Target Audience

This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.

Program Overview

This activity provides an overview of CAR T-cell development, available CAR T-cell products for blood cancers, and important side effects of CAR T-cell therapy.

Learning Objective

Upon completion of this activity, participants should be better able to:

  • Describe the current state of chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies

Post a comment to this article